Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Servier has exercised its option with Cellectis to acquire exclusive worldwide rights to UCART19, a TALEN gene-edited allogeneic chimeric antigen receptor T-cell (CAR-T) immunotherapy.
Subscribe to our email newsletter
UCART19 uses Cellectis’ allogeneic approach to develop CAR-T therapies that engineer T-cells from non-patient donors for use in several patients.
The immunotherapy candidate is about to enter Phase 1 development for chronic lymphocytic leukemia and acute lymphoblastic leukemia.
Under the deal, Cellectis will receive an upfront payment of $38.2m and more than $300m in milestones, R&D financing and royalties on commercial sales.
Separately, Servier has signed a global license and collaboration agreement with Pfizer to co-develop and commercialize UCART19.
The companies did not disclose financial terms of the agreement. They will work together on clinical development including sharing costs.
Pfizer will be responsible to commercialize UCART19 in the US and Servier will marketing rights in countries outside the US.
Pfizer president of worldwide research and development Mikael Dolsten said: "This collaboration on the development of the UCART19 asset builds on Pfizer’s position in the CAR-T space and our growing portfolio of investigational immuno-oncology assets, which is a major priority for our oncology business."